Beam Therapeutics Inc

NASDAQ:BEAM   4:00:00 PM EDT
43.18
-1.19 (-2.68%)
6:07:43 PM EDT: $42.50 -0.68 (-1.58%)
Earnings Announcements

Beam Therapeutics Announces Portfolio Progress And Reports Q3 Financial Results

Published: 11/07/2022 11:56 GMT
Beam Therapeutics Inc (BEAM) - Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results.
Ind-enabling Studies Underway for Beam-301 for Treatment of Gsdia.
Qtrly Loss per Share $1.56.
Qtrly License and Collaboration Revenue $15.8 Million Versus $0.7 Million.
Beam Therapeutics - Cash, Cash Equivalents and Marketable Securities Were $1.1 Billion As of Sept 30, 2022, As Compared to $965.6 Million As of Dec 31, 2021.
Q3 Earnings per Share View $-1.31, Revenue View $7.9 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $12.53 Million
Adjusted EPS is expected to be -$1.38

Next Quarter Revenue Guidance is expected to be $8.91 Million
Next Quarter EPS Guidance is expected to be -$1.38

More details on our Analysts Page.